Advertisement
UK markets close in 7 hours 22 minutes
  • FTSE 100

    8,121.96
    +43.10 (+0.53%)
     
  • FTSE 250

    19,752.50
    +150.52 (+0.77%)
     
  • AIM

    755.63
    +2.51 (+0.33%)
     
  • GBP/EUR

    1.1659
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.2517
    +0.0006 (+0.05%)
     
  • Bitcoin GBP

    51,364.83
    +201.89 (+0.39%)
     
  • CMC Crypto 200

    1,388.56
    -7.98 (-0.57%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    83.97
    +0.40 (+0.48%)
     
  • GOLD FUTURES

    2,356.90
    +14.40 (+0.61%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,670.61
    +386.07 (+2.23%)
     
  • DAX

    18,032.44
    +115.16 (+0.64%)
     
  • CAC 40

    8,040.96
    +24.31 (+0.30%)
     

2 Under-the-Radar Biotech Stocks to Buy in 2023

2 Under-the-Radar Biotech Stocks to Buy in 2023

With that said, let's consider two biotech stocks, neither of which is a household name, that could deliver solid returns over the next five years and more: Exelixis (NASDAQ: EXEL) and Sarepta Therapeutics (NASDAQ: SRPT). Oncology is one of the most fiercely competitive therapeutic areas in the biotech industry. Exelixis, a mid-cap biotech, is just a small player in the field.